Table 2 Clinical data of the high-SLC25A19 expression group and the low-SLC25A19 expression.
From: SLC25A19 is a key prognostic marker for hepatocellular carcinoma
Variables | Total n = 374 | High expression n = 187 | Low expression n = 187 | |
|---|---|---|---|---|
Age | <= 65 | 235 (62.83%) | 125 (66.84%) | 110 (58.82%) |
> 65 | 138 (36.9%) | 61 (32.62%) | 77 (41.18%) | |
Unknown | 1 (0.27%) | 1 (0.53%) | 0 (0%) | |
Grade | G1 | 55 (14.71%) | 20 (10.7%) | 35 (18.72%) |
G2 | 178 (47.59%) | 79 (42.25%) | 99 (52.94%) | |
G3 | 124 (33.16%) | 76 (40.64%) | 48 (25.67%) | |
G4 | 12 (3.21%) | 9 (4.81%) | 3 (1.6%) | |
Unknown | 5 (1.34%) | 3 (1.6%) | 2 (1.07%) | |
M | M0 | 268 (71.66%) | 140 (74.87%) | 128 (68.45%) |
M1 | 4 (1.07%) | 2 (1.07%) | 2 (1.07%) | |
Unknown | 102 (27.27%) | 45 (24.06%) | 57 (30.48%) | |
N | N0 | 254 (67.91%) | 132 (70.59%) | 122 (65.24%) |
N1 | 4 (1.07%) | 3 (1.6%) | 1 (0.53%) | |
Unknown | 116 (31.02%) | 52 (27.81%) | 64 (34.22%) | |
T | T1 | 183 (48.93%) | 75 (40.11%) | 108 (57.75%) |
T2 | 95 (25.4%) | 60 (32.09%) | 35 (18.72%) | |
T3 | 80 (21.39%) | 45 (24.06%) | 35 (18.72%) | |
T4 | 13 (3.48%) | 7 (3.74%) | 6 (3.21%) | |
Unknown | 3 (0.8%) | 0 (0%) | 3 (1.6%) | |
Gender | Female | 121 (32.35%) | 71 (37.97%) | 50 (26.74%) |
Male | 253 (67.65%) | 116 (62.03%) | 137 (73.26%) | |
Stage | Stage I | 173 (46.26%) | 71 (37.97%) | 102 (54.55%) |
Stage II | 87 (23.26%) | 52 (27.81%) | 35 (18.72%) | |
Stage III | 85 (22.73%) | 49 (26.2%) | 36 (19.25%) | |
Stage IV | 5 (1.34%) | 2 (1.07%) | 3 (1.6%) | |
Unknown | 24 (6.42%) | 13 (6.95%) | 11 (5.88%) | |
